David Rodeberg, MD
Disclosures: Nothing to disclose
FF Principal Investigator/Program Director (Last, first, middle):_______________________________________________

 

 

 

BIOGRAPHICAL SKETCH

 

 

NAME

David Anthony Rodeberg, MD

POSITION TITLE

Chief, Division of Pediatric Surgery

Co-Director and Surgeon in Chief of the James and Connie Maynard Children’s Hospital

eRA COMMONS USER NAME (credential, e.g., agency login)

RODEBERGDA

EDUCATION/TRAINING  (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)

INSTITUTION AND LOCATION

DEGREE

(if applicable)

YEAR(s)

FIELD OF STUDY

Viterbo College

 

BS

1980 - 1984

Chemistry/Biology

University of Wisconsin Medical School

 

MD

1985 - 1989

Medicine

University of Cincinnati Medical Center

 

Internship

1989 - 1990

Surgery

University of Cincinnati Medical Center

 

Residency

1990 - 1997

Surgery

Johns Hopkins Hospital

Fellow

1997 - 1999

Pediatric Surgery

  1. Personal Statement.

I am a member of the East Carolina University Department of Surgery, the Verneda and Clifford Kiehn Professor of Pediatric Surgery and Chief, Division of Pediatric Surgery. In addition to my academic role on the ECU faculty, I am Surgeon-in-Chief of the Maynard Children's Hospital and Medical Director for Operative Services at Vidant Medical Center. In these roles I have gained valuable experience in strategic planning with diverse stakeholders, project management, financial oversight as well as external auditing and funding agencies. I completed a general surgery internship and residency at the University of Cincinnati and a fellowship in pediatric surgery at The Johns Hopkins. I have previously worked on the faculty of the Mayo Clinic in Minnesota and subsequently the Children’s Hospital of Pittsburgh and the University of Pittsburgh School of Medicine.

I have been involved in both translational and clinical cancer research. The translational research initially involved the development of peptide-based dendritic cell vaccine immunotherapy and immune modulation for the treatment of rhabdomyosarcoma (RMS). Subsequently my work continued in sarcomas but shifted to the receptor/ligand complexes involved in tumor cell:immune cell interactions including NKG2D:MICA and Notch:Delta/Jagged. My clinical research and academic publications have focused predominately on pediatric sarcomas as a result of my work in the Children’s Oncology Group (COG) and the International Soft Tissue Sarcoma Consortium (INSTRuCT). INSTRuCT is a collaboration of North American and European oncology study groups (COG, EpSSG, CWS). In 2000 I became involved in the Intergroup Rhabdomyosarcoma Study Group (IRSG), now called the Soft Tissue Sarcoma (STS) committee of the COG. In my 20 years on this committee I have been the surgical investigator on a number of STS sponsored clinical trials. I have also published extensively on rhabdomyosarcoma.

I have held leadership positions within COG and INSTRuCT. I am a member of the STS Steering Committee and have been the Surgical Discipline Liaison (Vice-Chair) since 2007. I have been the lead surgeon on the INSTRuCT steering committee since 2017. In addition to my activity within COG and INSTuCT I am currently the American Pediatric Surgical Association (APSA) Vice-Chair for the Cancer Committee and will be the Chair in 2021.

 

B. Positions and Honors

Positions and Employment

1989-1990              University of Cincinnati Medical Center, Dept of Surgery, Cincinnati, OH; Intern

1990-1997              University of Cincinnati Medical Center, Dept of Surgery, Cincinnati, OH; Resident

1997-1999              John Hopkins Hospital, Dept of Surgery, Baltimore, MD; Pediatric Surgery Fellow

2000-2005              Mayo Clinic College of Medicine, Dept of Pediatric Surgery, Rochester, MN; Assistant Professor of Surgery

2002-2005              Mayo Clinic, Dept of Surgery, Div of Pediatric Surgery, Rochester, MN; Consultant

2005-2010              University of Pittsburgh School of Medicine, Dept of Pediatric Surgery, Pittsburgh, PA; Assistant Professor

2010-present   East Carolina University, Brody School of Medicine, Dept of Surgery, Greenville, NC; Professor, Chief, Division of Pediatric Surgery

2010-present  Vidant Medical Center, Greenville, NC; Surgeon in Chief of the James

                       and Connie Maynard Children’s Hospital

2014-present              Vidant Medical Center, Greenville NC; Medical Director for Operative Services

 

Other Pertinent Experience and Professional Memberships

2000- present             Fellow, American Academy of Pediatrics

2000- present             Fellow, American College of Surgeons

2000- present             Member, Children’s Oncology Group

Vice-Chair, Soft Tissue Sarcoma Committee

Steering Committee, Surgical Discipline Committee

2001- present            Member, American Pediatric Surgical Association

                                                 Vice-Chair, Cancer Committee         

                           

Recent Honors

Verneda and Clifford Kiehn Distinguished Professor in Pediatric Surgery             2010-2011

Centennial Leadership Award, East Carolina University                                                2013

Who’s Who in Medicine                                                                                                         2013

Top Doctors Award                                                                                                                      2014

Health Sciences Author Recognition Award                                                                            2015

Health Sciences Author Recognition Award                                                                            2019

 

  1. Contributions to Science

              INSTRuCT

                            INSTRuCT Is a collaboration between the COG, CWS, and the EpSSG to create a combined database for sarcoma patients that had been enrolled in therapeutic trials for each of the cooperative groups. This combined database will be used for clinical research projects and may be accessed by anyone, but project proposals must first be approved by the INSTRuCT Steering Committee. I have been the surgical representative on the steering committee since its inception. The database is still under active construction and so is not yet accessible. The surgical committee for INSTRuCT, six surgeons two from each cooperative group, has also initiated additional projects to facilitate the surgical care of sarcoma patients. We have initiated best practice surgical guidelines for the treatment of sarcoma at different sites that have been approved an R applicable for all surgeons worldwide. When appropriate these have been written in conjunction with the INSTRuCT radiation oncologist to provide guidelines for total local control.

 

Surgical management of extremity rhabdomyosarcoma: A consensus opinion from the Children's Oncology Group, the European Pediatric Soft-Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe. Morris CD, Tunn PU, Rodeberg DA, Terwisscha van Scheltinga S, Binitie O, Godzinski J, Dall'Igna P, Million L, Hawkins DS, Koscielniak E, Bisogno G, Rogers TN. Pediatr Blood Cancer. 2020 Aug 9:e28608. PMID: 32776456

 

Local treatment of rhabdomyosarcoma of the female genital tract: Expert consensus from the Children's Oncology Group, the European Soft-Tissue Sarcoma Group, and the Cooperative Weichteilsarkom Studiengruppe. Lautz TB, Martelli H, Fuchs J, Chargari C, Smeulders N, Granberg CF, Wolden SL, Sparber-Sauer M, Hawkins DS, Bisogno G, Koscielniak E, Rodeberg DA, Seitz G; INSTRuCT group. Pediatr Blood Cancer. 2020 Aug 6:e28601. PMID: 32762004

 

We have also initiated and are currently working through the different cooperative leaderships to standardize the surgical data collection forms that would be used for all cooperative groups. This will help standardize the data that is collected and facilitate its incorporation into the combined database. This will also hopefully minimize incomplete data.

 

              STS COG

                            During my time on the sarcoma committee I have been involved in a number of clinical trials. Involvement in these trials includes initiation and development of the study design for local control, validation of data, and publication of study results. There are several areas that I have initiated and advanced to improve the surgical therapy for rhabdomyosarcoma. It has been acknowledged and known that initial resection of primary tumors can improve the outcomes of patients. The standard of care after that was to use a combination of predominantly radiation and some surgical resection to achieve local control after the initiation of chemotherapy. However, the dosing of radiation required frequently resulted in complications that impacted the quality of life for patients. Therefore, I proposed performing a delayed primary excision after the initiation of chemotherapy with a modulation of the radiation dose based upon the completeness of resection. This change in the treatment paradigm resulted in a significant number of patients receiving a dose of radiation therapy that was decreased by approximately 25%. The outcome for these patients was no worse than historical controls and now subsequent studies have demonstrated that outcomes are potentially improved in patients that undergo a delayed primary excision. We are now making this part of our standard local control paradigm and applying it to a broader selection of patients.

 

Benefit of delayed primary excision in rhabdomyosarcoma: A report from the Children's Oncology Group (COG). Lautz TB, Chi YY, Li M, Wolden SL, Casey DL, Routh JC, Granberg CF, Binite O, Rudzinski ER, Hawkins DS, Venkatramani R, Rodeberg DA. Cancer. 2020 Oct 20. PMID: 33079399

 

Delayed primary excision with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee. Rodeberg DA, Wharam MD, Lyden ER, Stoner JA, Brown K, Wolden SL, Paidas CN, Donaldson SS, Hawkins DS, Spunt SL, Arndt CA. Int J Cancer. 2015 Jul 1;137(1):204-11. PMID: 25418440

 

Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study. Breneman J, Meza J, Donaldson SS, Raney RB, Wolden S, Michalski J, Laurie F, Rodeberg DA, Meyer W, Walterhouse D, Hawkins DS. Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):720-6. PMID: 22104356

 

Another area that I have initiated was the question of what to do with a mass at the end of therapy. Many patients have a residual mass at the end of all planned therapy. A review of patients undergoing excision of a residual mass at the end of all therapy demonstrated that they had no improved outcome and that the completeness of resection was frequently inadequate and resulted in significant morbidity. These results have been confirmed with subsequent studies. Because of these findings we are now discouraging any surgical intervention in patients with the residual mass.

 

Relationship between tumor response at therapy completion and prognosis in patients with Group III rhabdomyosarcoma: A report from the Children's Oncology Group. Lautz TB, Chi YY, Tian J, Gupta AA, Wolden SL, Routh JC, Casey DL, Dasgupta R, Hawkins DS, Rodeberg DA. Int J Cancer. 2020 Sep 1;147(5):1419-1426. PMID: 32012255

 

Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the children's oncology group. Rodeberg DA, Stoner JA, Hayes-Jordan A, Kao SC, Wolden SL, Qualman SJ, Meyer WH, Hawkins DS. J Clin Oncol. 2009 Aug 1;27(22):3705-11. PMID: 19470937

 

Patients with regional lymph node disease in certain select sites have a worse prognosis. This has driven the paradigm to obtain surgical lymph node evaluation in patients with extremity and paratesticular, greater than 10 yrs old, rhabdomyosarcoma. I evaluated regional lymph node disease in patients with rhabdomyosarcoma and identified, using gene array technology, that the patients with regional nodal disease had a distinct gene array pattern and that patients with alveolar histology the presence of regional nodal disease had a prognosis similar to patients with metastatic disease. These findings have been replicated in European studies and have resulted in changes to the requirements for surgical nodal evaluation to include patients with alveolar histology (FOXO fusion positive) and those patients with primary tumors of the trunk. Looking specifically at paratesticular tumors we have determined that the optimal number of retroperitoneal lymph nodes that must be removed is between 7-12 with the optimal number between 10-12. In addition, we corroborated the results from CWS showing that hemi-scrotectomy after scrotal violation is not beneficial. All of these findings have resulted in changes to our standard surgical treatment paradigm for these patients.

 

Impact of local control and surgical lymph node evaluation in localized paratesticular rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. Routh JC, Dasgupta R, Chi YY, Shnorhavorian M, Tian J, Walterhouse DO, Breneman J, Wolden SL, Arndt CA, Hawkins DS, Rodeberg DA. Int J Cancer. 2020 Dec 1;147(11):3168-3176. PMID: 32525556

 

Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group. Rodeberg DA, Garcia-Henriquez N, Lyden ER, Davicioni E, Parham DM, Skapek SX, Hayes-Jordan AA, Donaldson SS, Brown KL, Triche TJ, Meyer WH, Hawkins DS. J Clin Oncol. 2011 Apr 1;29(10):1304-11. PMID: 21357792

 

 

 

    1. Research Support

 

2017-present Rodeberg (Surgical Investigator)

ARST1431 A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide    (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

 

2019-present Rodeberg (Surgical Investigator)

A Safety, Pharmacokinetic and Efficacy Study of a Gamma-Secretase Inhibitor, Nirogacestat (PF-03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors

 

2010-2019              Rodeberg (Surgical PI)

                        A Pilot Study to Evaluate  Novel Agents (Temozolomide and IMC-A12    (ARST08P1)

                        [Anti-IGF-IR Monoclonal Antibody, IND #100947, NSC # 742460]) in Combination with    

      Intensive Multi-Agent Interval Compressed Therapy for Patients with High-Risk           

                                          Rhabdomyosarcoma.

 

2006 2014              Rodeberg (Surgical PI)

                                          Soft Tissue Sarcoma Study Protocol- Intermediate Risk Rhabdomyosarcoma  (ARST0531)    

                                          Funded by:  Children’s Oncology Group / National Institutes of Health

                 This is a randomized study of Vincristine, Actinomycin-D, Cyclophosphamide (VAC) versus

                 VAC alternating with Vincristine and Irinotecan (VI) for patients with intermediate-risk       

                        Rhabdomyosarcoma.

 

2006 - 2008                Rodeberg (Surgical PI)

                                          Soft Tissue Sarcoma Study Protocol- High Risk Rhabdomyosarcoma  (ARST0431)                      

                                          Funded by:  Children’s Oncology Group / National Institutes of Health

This is a study trial utilizing intensive multi-agent therapy, including dose-compressed cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for patients with high-risk rhabdomyosarcoma.

 

 

Page